


Supplemental Figures


Overall	Events, n	Median, months (95% CI)
Overall (n = 68)	31	11.1 (8.4, 18.5)



Patients at risk:

— 68 67 49 29 14 12 7 4 4 4 1 1 1 0 0


Age	Events, n	Median, months (95% CI)
<75 years (n = 41)	16	12.4 (8.4, ne)
≥75 years (n = 27)	15	10.1 (5.8, 18.5)
<80 years (n = 55)	24	11.1 (9.5, ne)
≥80 years (n = 13)	7	10.1 (5.6, 18.5)



Patients at risk:

— <75 years 41 40 32 16 8 7 5 4 4 4 1 1 1 0 0
 — ≥75 years 27 27 17 13 6 5 2 0 0 0 0 0 0 0 0
 — <80 years 55 54 42 24 11 10 6 4 4 4 1 1 1 0 0
 — ≥80 years 13 13 7 5 3 2 1 0 0 0 0 0 0 0 0


Line of therapy	Events, n	Median, months (95% CI)
Treatment-naïve (n = 31)	13	10.8 (6.9, ne)
Previously treated (n = 37)	18	11.1 (9.5, 18.5)



Patients at risk:

— Treatment-naïve 31 30 21 10 5 4 3 2 2 2 0 0 0 0 0
 — Previously treated 37 37 28 19 9 8 4 2 2 2 1 1 1 0 0

Prior platinum-based chemotherapy for metastatic disease	Events, n	Median, months (95% CI)
Yes (n = 36)	17	12.4 (9.5, 18.5)



Patients at risk:

— Yes 36 36 27 18 9 8 4 2 2 2 1 1 1 0 0

Figure S1. Duration of response according to independent review. CI, confidence interval; ne, not estimable.